Serum concentration of eicosapentaenoic acid is associated with cognitive function in patients with coronary artery disease

Shusuke Yagi1,*, Tomoya Hara1,†, Rie Ueno1, Ken-ichi Aihara2, Dajiu Fukuda3, Akira Takashima1, Junko Hotchi1, Takayuki Ise1, Koji Yamaguchi1, Takeshi Tobiume1, Takashi Iwase1, Hirotugu Yamada1, Takeshi Soeki1, Tetsuzo Wakatsuki1, Michio Shimabukuro3, Masashi Akaike4 and Masataka Sata1

Abstract

Background: Recent studies have shown that intake of n-3 polyunsaturated fatty acids (PUFAs) is associated with reduced risk of cognitive impairment and coronary artery disease (CAD); however, it is currently unknown whether reduced serum n-3 PUFA is associated with cognitive impairment in patients with CAD.

Methods: We retrospectively evaluated cognitive function with the mini-mental state examination (MMSE), serum levels of PUFAs (including eicosapentaenoic acid [EPA], docosahexaenoic acid [DHA], dihomogammalinolenic acid [DGLA], and arachidonic acid [AA]), cardiovascular risk factors (hypertension, dyslipidemia, diabetes mellitus, cerebrovascular disease, and history of current/previous smoking), and parameters of cardiac function (left ventricular ejection fraction and brain natriuretic peptide levels) in 146 Japanese CAD patients. The associations between the MMSE scores and the other parameters were evaluated.

Results: Pearson correlation analysis showed that EPA (R = 0.25, P <0.01), EPA/AA ratio (R = 0.22, P = 0.01), and left ventricular ejection fraction (R = 0.15, P = 0.04) were positively associated with MMSE score, and that age (R = −0.20, P <0.01) and brain natriuretic peptide levels (R = −0.28, P <0.01) were inversely associated with MMSE score. Multiple regression analysis showed that age (P <0.05) was negatively associated with MMSE score, while EPA (P <0.01) and EPA/AA ratio (P <0.05) were positively associated with MMSE score; however, sex; body mass index; left ventricular ejection fraction; levels of DHA, AA, and DGLA; DHA/AA ratio; brain natriuretic peptide; and presence of hypertension, dyslipidemia, diabetes mellitus, cerebrovascular disease, and history of current/previous smoking were statistically excluded.

Conclusions: Serum EPA concentration is associated with cognitive function in patients with CAD, suggesting that a low serum EPA level is a risk factor for cognitive impairment independent of cardiac function, including left ventricular ejection fraction. This correlation potentially lends further support to a role of dietary n-3 PUFAs in preventing the cognitive decline in CAD patients.

Keywords: Eicosapentaenoic acid, n-3 polyunsaturated fatty acids, Cognitive function, Mini-mental state examinations, Coronary artery disease
Background
Cardiovascular disease has recently been implicated as a major factor in the development of dementia, as these diseases may be linked by shared common risks and pathogenic elements [1,2]. Accumulation of cardiovascular risk factors therefore leads to cognitive impairment. In addition, hypoxia/ischemia resulting from reduced cerebral blood flow due to cardiac dysfunction may be associated with dementia. Conversely, dementia itself could be an independent cardiovascular risk factor; patients with dementia have lifestyle-related problems, such as inappropriate food or alcohol intake, sedentary activity, and psychosocial stress, including depression [3]. Therefore, the modification of these lifestyle-related problems could be strategies for coronary artery disease (CAD) and dementia prevention. While several pharmacological agents, including cholinesterase inhibitors [4], have been developed for dementia, sufficiently effective and curative treatments have not yet been established. Therefore, the identification of residual risk factors is important for dementia prevention.

The Japan Eicosapentaenoic Acid Lipid Intervention Study showed that long-term use of eicosapentaenoic acid (EPA) is effective for prevention of major coronary events in Japanese hypercholesterolemic patients [5]. In addition, recent studies demonstrated that consumption of fish and n-3 polyunsaturated fatty acids (PUFAs) reduced the incidence of cognitive impairment [6]. These studies indicate that a reduced serum level of n-3 PUFAs may be a risk factor for both CAD and cognitive impairment.

However, it is currently unknown whether reduced serum levels of n-3 PUFAs are associated with cognitive impairment, and more specifically, which components of PUFAs are associated with cognitive function in CAD patients. Therefore, the aim of this study was to investigate the association between cognitive function and n-3 PUFA levels (including eicosapentaenoic acid [EPA], docosahexaenoic acid [DHA], dihomogammalinolenic acid [DGLA], and arachidonic acid [AA]) in CAD patients, and to identify which components of PUFAs are associated with cognitive function in these patients.

We hypothesized that decreased level of EPA would be associated with cognitive impairment in patients with CAD.

Material and methods
Patients and study design
In patients with CAD, serum PUFA levels were measured for identification of residual risk factors for CAD. In addition, patients underwent mini-mental state examinations (MMSE) to screen cognitive function [1]. We retrospectively reviewed 146 consecutive Japanese patients diagnosed with CAD in the Department of Cardiology at Tokushima University Hospital between April 2013 and March 2014.

Patients with CAD were defined as patients with a history of myocardial infarction, angiographic evidence of at least 50% stenosis by area in at least 1 coronary artery, evidence of exercise-induced ischemia, or history of coronary revascularization. The exclusion criteria were as follows: use of fish oil supplements or n-3 fatty acid-containing drugs or a history of myocardial infarction.

Table 1 Clinical characteristics of subjects

| Variables                                      | Number of patients |
|------------------------------------------------|--------------------|
| Number of patients                            | 146                |
| Mini-mental state examination score           | 27.8 ± 3.1         |
| Male, n (%)                                   | 111 (76.0%)        |
| Age, y                                        | 70.9 ± 8.6         |
| Body mass index, kg/m²                        | 23.5 ± 3.4         |
| Systolic blood pressure, mmHg                 | 127 ± 16.3         |
| Diastolic blood pressure, mmHg                | 71 ± 11.6          |
| Low-density lipoprotein cholesterol, mg/dL     | 96.0 ± 34.4        |
| Triglycerides, mg/dL                          | 124.5 ± 70.3       |
| High-density lipoprotein cholesterol, mg/dL    | 55.0 ± 14.7        |
| HbA1c, %                                      | 6.7 ± 5.5          |
| Fasting plasma blood glucose, mg/dL           | 130.0 ± 58.7       |
| Brain natriuretic peptide, pg/mL              | 151.6 ± 274.2      |
| Left ventricular ejection fraction, %         | 58.6 ± 11.2        |
| Fatty acids                                    |                    |
| Docosahexaenoic acid, µg/mL                   | 132.5 ± 52.2       |
| Eicosapentaenoic acid, µg/mL                  | 68.9 ± 40.4        |
| Arachidonic acid, µg/mL                       | 173.0 ± 43.4       |
| Dihomogammalinolenic acid, µg/mL              | 34.5 ± 11.4        |
| Complications                                  |                    |
| Dyslipidemia, n (%)                            | 126 (86.3%)        |
| Hypertension, n (%)                            | 131 (89.7%)        |
| Diabetes mellitus, n (%)                      | 80 (54.8%)         |
| Cerebrovascular disease, n (%)                 | 25 (17.1%)         |
| Smoking, n (%)                                 | 108 (74.0%)        |
| Drugs                                          |                    |
| ACEI/ARB, n (%)                                | 91 (62.3%)         |
| β-blockers, n (%)                              | 53 (36.3%)         |
| Calcium channel blockers, n (%)                | 62 (42.5%)         |
| Statins, n (%)                                 | 123 (84.2%)        |
| Ezetimibe, n (%)                               | 8 (5.5%)           |
| Diuretics loop, n (%)                          | 27 (18.5%)         |
| Mineralocorticoid antagonists, n (%)           | 7 (4.8%)           |

Unless indicated otherwise, data are presented as the mean ± standard deviation.
ACEI, angiotensin converting enzyme inhibitors; ARB, angiotensin II receptor blockers.
Within 1 month. In addition, patients with symptomatic active malignant diseases or liver dysfunction (aspartate aminotransferase levels >100 IU/L, alanine aminotransferase levels >100 IU/L) were also excluded.

Hypertensive patients were defined as those with a systolic blood pressure of ≥140 mmHg and/or diastolic blood pressure of ≥90 mmHg and/or individuals receiving antihypertensive medications. Dyslipidemic patients were defined as those with a low-density lipoprotein cholesterol level (LDL-C) of ≥140 mg/dL, a triglyceride level of ≥150 mg/dL, a high-density lipoprotein cholesterol level (HDL-C) of <40 mg/dL, or individuals receiving lipid-lowering medications. Diabetic patients were defined as individuals receiving insulin or oral hypoglycemic agents or those with an HbA1c level of ≥6.5%, fasting plasma glucose level of 126 mg/dL, or non-fasting plasma glucose level of ≥200 mg/dL.

Serum fatty acid composition, including levels of EPA, DHA, DGLA, and AA, was measured by gas–liquid chromatography at a commercially available laboratory (SRL, Tokyo, Japan).

Since n-6 PUFAs, including AA, are often considered to be pro-inflammatory fatty acids and the EPA/AA ratio is associated with a low incidence of cardiac events [7], EPA/AA and DHA/AA ratios were also calculated.

In addition, other biochemical parameters, including LDL-C, HDL-C, triglycerides, fasting plasma glucose, and HbA1c, were also measured.

Cardiac function was evaluated by measuring brain natriuretic peptide (BNP), a biomarker which represents left ventricular endodiastolic pressure, and left ventricular ejection fraction (LVEF) evaluated by echocardiography. The LVEF was calculated using the modified Simpson’s method with the apical 4-chamber and 2-chamber views.

Cognitive function was evaluated by MMSE, which is widely used as a screening tool for assessment of cognitive function [8].

This study protocol was approved by the Tokushima University Hospital Ethics Committee.

**Statistical analysis**

Continuous variables were averaged and expressed as the mean ± standard deviation, and categorical parameters were expressed as a percentage. MMSE scores and BNP levels were natural log transformed for statistical analysis because of non-normal distributions. Associations between CAD risk factors and MMSE scores were

**Table 2 Pearson correlation analysis between MMSE scores and cardiovascular risk factors**

| Variables                                | R    | P-value |
|------------------------------------------|------|---------|
| Age                                      | −0.20| <0.01   |
| Sex                                      | -    | 0.30    |
| Body mass index                          | 0.09 | 0.23    |
| DHA                                      | 0.12 | 0.06    |
| EPA                                      | 0.25 | <0.01   |
| AA                                       | 0.1  | 0.99    |
| DGLA                                     | −0.001| 0.20 |
| EPA/AA                                   | 0.22 | 0.01    |
| DHA/AA                                   | 0.10 | 0.20    |
| Left ventricular ejection fraction       | 0.15 | 0.04    |
| Brain natriuretic peptide               | −0.28| <0.01   |
| Hypertension                            | -    | 0.96    |
| Dyslipidemia                             | -    | 0.89    |
| Diabetes mellitus                       | -    | 0.37    |
| Cerebrovascular disease                  | -    | 0.79    |
| Current/previous smoker                 | -    | 0.12    |

**MMSE**, mini-mental state examination; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; AA, arachidonic acid; DGLA, dihomogammalinoenic acid.
determined by the Student’s t-test or the Pearson’s correlation analysis. Multiple regression analysis (standard least squares method) was used to assess the degrees of association between the CAD risk factor variables and the MMSE scores. Residuals and residual vs. fit plots were examined to ensure homoscedasticity.

All statistical analyses were performed using JMP 10 software. Statistical significance was defined as P <0.05.

Results
Clinical characteristics of subjects
Patient characteristics are shown in Table 1. The mean MMSE score was 27.8 ± 3.1, indicating that subjects generally had mild cognitive impairment. The serum concentration of n-3 PUFAs, including EPA and DHA, and n-6 PUFAs, including AA and DGLA, are shown in Figure 1 by patient age and sex. EPA and DHA concentrations were the highest among patients aged ≥80 years, and levels of EPA, DHA, DGLA, and AA were higher in women than in men.

Correlation between n-3 PUFAs and MMSE score
The Pearson correlation analysis showed that levels of EPA, EPA/AA ratio, and LVEF were positively associated with MMSE score, and that age and BNP was inversely associated with MMSE score (Table 2, Figure 2). There were no relationships between MMSE score and body mass index or levels of DHA, AA, DGLA, and DHA/AA ratio (Additional file 1: Tables S1 and S2). Multiple regression analysis was then performed to elucidate independent determinants of MMSE score; age (P <0.05) was negatively associated with MMSE score, while EPA levels (P <0.01) and EPA/AA ratio (P <0.05) were positively associated with MMSE score. However, sex; body mass index; levels of DHA, AA, DGLA, and DHA/AA ratio; LVEF; levels of BNP; presence of hypertension, dyslipidemia, diabetes mellitus, and cerebrovascular disease; and history of current/previous smoking were statistically excluded (Table 3).

Discussion
The present study demonstrated that decreased serum levels of EPA and a reduced EPA/AA ratio are associated with cognitive impairment in patients with CAD, indicating that decreased EPA is a risk factor for development of cognitive impairment this patient population. AA levels showed no association with MMSE scores, while low EPA levels were independently correlated with MMSE scores. Therefore, EPA/AA did not increase the predictive power of EPA alone. In addition, the Pearson correlation analysis exhibited an association between MMSE scores and LVEF or BNP; however, multiple regression in an age-adjusted model showed no association.
Although there is a possibility of confounding between cardiac function and age, our results indicate that MMSE scores were associated with EPA levels independent of cardiac function.

It has been reported that fish intake is associated with cognitive function [9,10], and n-3 PUFA-containing food improves cognitive function [11]. The exact mechanisms of EPA on neuronal function are unknown; however, EPA is involved in endothelial-dependent vascular function and plays important roles in the prevention of microcirculatory insufficiency. Therefore, one possible mechanism is that decreased EPA results in microcirculation insufficiency in the brain, thus leading to ischemia-induced brain damage. It has been reported that EPA enhances endothelial expression of nitric oxide synthase, and activation of endothelial nitric oxide synthase leads to vasodilation and endothelial protection [12,13]. Reduced nitric oxide synthase-induced microcirculation insufficiency may be involved in the development of cognitive impairment. Brain microvascular insufficiency, including cerebral white matter disease, is an early marker of cognitive impairment [14,15]. Thus, in patients with very mild cognitive impairment, such as those who were included in this study, microcirculation insufficiency rather than amyloid β deposition, the cause of Alzheimer’s disease, may be the predominant contributor to vascular dementia.

It has been reported that vascular inflammation is associated with cognitive function [16]. EPA is known to have the ability to attenuate tumor necrosis factor-α-induced upregulation of vascular cell adhesion molecule-1, intercellular adhesion molecule-1, and monocyte chemoattractant protein-1 [17]. The anti-inflammatory effects of EPA might contribute to the prevention of cognitive impairment.

A previous meta-analysis demonstrated that subjects with predementia syndrome had significantly lower levels of EPA but not DHA or total n-3 PUFA [18]; thus, serum EPA may be a more sensitive biomarker for prediction of cognitive impairment compared to serum DHA. It has also been reported that administration of n-3 PUFA to patients with very mild Alzheimer’s disease (MMSE >27 points) delayed the rate of cognitive dysfunction, indicating the importance of n-3 PUFA on brain function in early stages of cognitive impairment [19].

In addition, EPA is converted into DHA in the liver and at the blood-brain barrier and has been shown to cross the blood-brain barrier after dietary supplementation, thereby suggesting that EPA plays important roles in cognitive function after conversion into DHA [20,21]. EPA could be a rich source of DHA and may compensate for reduced levels of DHA in the brain; decreased serum EPA may thus be a more profound indicator of cognitive function than decreased serum DHA.

The present study had several limitations. In particular, this was a retrospective study with a small sample size in a single center. Larger clinical cohort studies are needed to clarify the effects of EPA on cognitive function.

### Conclusions

Serum EPA concentration rather than serum DHA concentration is associated with cognitive function in patients with CAD, suggesting that a low serum EPA level is a risk factor for cognitive impairment independent of cardiac function. Our data support a role of dietary n-3 PUFAs in preventing the cognitive decline in CAD patients.

---

Table 3 Multiple regression analysis for determinants of degree of MMSE score in patients with CAD

| Variables                     | Coefficient | 95% confidence interval | P-value |
|-------------------------------|-------------|-------------------------|---------|
| **Model 1**                   |             |                         |         |
| Age, years                    | −0.004      | −0.007 to −0.001        | 0.02    |
| Male sex                      | 0.005       | 0.03 to 0.04            | 0.76    |
| Body mass index, kg/m²        | −0.0008     | −0.001 to 0.007         | 0.85    |
| Hypertension                  | 0.02        | −0.01 to 0.06           | 0.24    |
| Dyslipidemia                  | −0.001      | −0.04 to 0.03           | 0.91    |
| Diabetes mellitus             | 0.001       | −0.02 to 0.02           | 0.98    |
| Cerebrovascular disease       | −0.01       | −0.04 to 0.02           | 0.50    |
| Current/previous smoker       | 0.001       | −0.03 to 0.04           | 0.80    |
| EPA, μg/mL                    | 0.001       | 0.0003 to 0.002         | <0.01   |
| DHA, μg/mL                    | −0.0004     | −0.001 to 0.0003        | 0.22    |
| AA, μg/mL                     | 0.0001      | −0.001 to 0.0001        | 0.83    |
| DGLA, μg/mL                   | 0.001       | −0.002 to 0.004         | 0.45    |
| LVEF, %                       | 0.001       | −0.001 to 0.004         | 0.20    |
| BNP, pg/mL                    | −0.015      | −0.035 to 0.005         | 0.15    |
| **Model 2**                   |             |                         |         |
| Age, years                    | −0.003      | −0.006 to −0.0002       | 0.04    |
| Male sex                      | 0.002       | −0.03 to 0.04           | 0.89    |
| Body mass index, kg/m²        | 0.0008      | −0.006 to 0.008         | 0.83    |
| Hypertension                  | 0.02        | −0.02 to 0.05           | 0.37    |
| Dyslipidemia                  | 0.003       | −0.03 to 0.04           | 0.84    |
| Diabetes mellitus             | 0.002       | −0.03 to 0.04           | 0.85    |
| Cerebrovascular disease       | −0.01       | −0.03 to 0.02           | 0.58    |
| Current/previous smoker       | 0.003       | −0.03 to 0.04           | 0.85    |
| EPA/AA                        | 0.15        | 0.03 to 0.28            | 0.01    |
| DHA/AA                        | −0.04       | −0.15 to 0.07           | 0.42    |
| LVEF, %                       | 0.001       | −0.001 to 0.003         | 0.29    |
| BNP, pg/mL                    | −0.018      | −0.04 to 0.001          | 0.06    |

Model 1 $R^2 = 0.20; P < 0.05$.
Model 2 $R^2 = 0.17; P < 0.05$.

EPA, eicosapentaenoic acid; DHA, docosahexaenoic acid; AA, arachidonic acid; DGLA, dihomogammalinolenic acid; LVEF, left ventricular ejection fraction; BNP, brain natriuretic peptide.
Additional file

**Additional file 1: Table S1.** Pearson correlation analysis between left ventricular ejection fraction and serum levels of polysaturated fatty acids. **Table S2.** Pearson correlation analysis between brain natriuretic peptide levels and serum levels of polysaturated fatty acids.

**Abbreviations**
PUFAs: Polysaturated fatty acids; EPA: Eicosapentaenoic acid; DHA: Docosahexaenoic acid; DGLA: Dihomo-γ-linolenic acid; AA: Arachidonic acid; CAD: Coronary artery disease; MMSE: Mini-mental state examinations; LDL-C: Low-density lipoprotein cholesterol level; HDL-C: High-density lipoprotein cholesterol level.

**Competing interests**
The authors declare that they have no conflicts of interest to disclose.

**Authors’ contributions**
SY, TH, RU, DF, AT, JH, T Ise, KY, TT, T Iwase, HY, TS, TW, M Shimabukuro, MA, M Sata collected data and SY analyzed the data and wrote the manuscript. KA, MA, M Shimabukuro, and M Sata provided the suggestion for this study. All authors read and approved the final manuscript.

**Acknowledgements**
We thank the staff of the Hospital Information Center of Tokushima University Hospital for abstracting patients’ data from medical records. This work was supported in part by JSPS KAKENHI (Grant Number 25461131 and 25860605) and Actelion Academy Prize 2013.

**Author details**
1. Department of Cardiovascular Medicine, The University of Tokushima Graduate School of Health Biosciences, 3-18-15 Kuramato-cho, Tokushima-city, Tokushima 770-8503, Japan. 2. Department of Medicine and Bioregulatory Sciences, The University of Tokushima Graduate School of Health Biosciences, 3-18-15 Kuramato-cho, Tokushima-city, Tokushima 770-8503, Japan. 3. Department of Cardio-Diabetes Medicine, The University of Tokushima Graduate School of Health Biosciences, 3-18-15 Kuramato-cho, Tokushima-city, Tokushima 770-8503, Japan. 4. Department of Medical Education, The University of Tokushima Graduate School of Health Biosciences, 3-18-15 Kuramato-cho, Tokushima-city, Tokushima 770-8503, Japan.

**Received:** 22 July 2014 **Accepted:** 6 November 2014

**Published:** 4 December 2014

**References**
1. Kovacic JC, Castellano JM, Fuster V: The links between complex coronary disease, cerebrovascular disease, and degenerative brain disease. Ann N Y Acad Sci 2012, 1254:99–105.
2. Schmidt SL, Corea PL, Tonticino JC, Manhaes AC, Felix RM, Azevedo JC, Barbieri GB, Mendes MHF, Boechat Y, Cabral H, Schmidt CJ, Dohmann HF, Mesquita CT: Value of combining activated brain FDG-PET and cardiac MiBG for the differential diagnosis of dementia – Differentiation of dementia with Lewy bodies and Alzheimer disease when the diagnoses based on clinical and neuroimaging criteria are difficult. Clin Nucl Med 2008, 33:398–401.
3. O’Donnell M, Teo K, Gao P, Anderson C, Sleight P, Dans A, Marzona I, Bosch J, Probstfield J, Yusuf S: Cognitive impairment and risk of cardiovascular events and mortality. Eur Heart J 2012, 33:1777–1786.
4. Anand P, Singh B: A review on cholinesterase inhibitors for Alzheimer’s disease. Arch Pharm Res 2013, 36:375–399.
5. Yokoyama M, Orihara H, Matsuzaki M, Matsuzawa Y, Saito Y, Ishikawa Y, Oikawa S, Sasaki J, Hishida H, Itakura H, Kita T, Kitabatake A, Nakaya N, Sakata T, Shimada K, Shirato K, Matsuura Y, Japan JI: Incremental Effects of Eicosapentaenoic Acid on Cardiovascular Events in Statin-Treated Patients With Coronary Artery Disease – Secondary Prevention Analysis From JELIS. Circ J 2009, 73:1285–1290.
6. Folstein MF, Folstein SE, McHugh PR: “Mini-mental state”: A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975, 12:189–198.
7. Matsuzaki M, Yokoyama M, Saito Y, Origa H, Ishikawa Y, Oikawa S, Sasaki J, Hishida H, Itakura H, Kita T, Kitabatake A, Nakaya N, Sakata T, Shimada K, Shirato K, Matsuura Y, Japan JI: Incremental Effects of Eicosapentaenoic Acid on Cardiovascular Events in Statin-Treated Patients With Coronary Artery Disease – Secondary Prevention Analysis From JELIS. Circ J 2009, 73:1285–1290.
8. Folstein MF, Folstein SE, McHugh PR: “Mini-mental state”: A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975, 12:189–198.
9. Albaranese E, Dangour AD, Uauy R, Acosta D, Guerra M, Guerra SSG, Huang YQ, Jacobs KB, de Rodriguez J, Noviaga LH, Salas A, Sosa AL, Souza RM, Williams J, Ferri CP, Prince MJ: Dietary fish and meat intake and dementia in Latin America, China, and India: a 10/66 Dementia Research Group population-based study. Am J Clin Nutr 2009, 90:392–400.
10. Gillette-Guyonnet S, Van Kan GA, Andrieu S, Barberger-Gateau P, Ber C, Bonnefoy M, Dartiges JF, De Groot L, Ferry M, Galan P, Hercberg S, Jeandel C, Morris MC, Nourhashemi F, Payette H, Pouilain JP, Porter F, Roussel AM, Ritz P, Rolland Y, Vellas B: lana task force on nutrition and cognitive decline with aging. J Nutr Health Aging 2007, 11:132–135.
11. Scheltens P, Kamphuis P, Verhey F, Rikker GMG, Wurtman RJ, Wilkinson D, Tivisk J, Kurz A: Cognitive drug in mild Alzheimer’s disease: A randomized, controlled trial. Alzheimer’s Dementia 2010, 6:1–10.
12. Tardivel S, Goussé-Dupont A, Robert V, Pourci NL, Gymberg A, Lacour B: Protective Effects of EPA and Deleterious Effects of DHA on eNOS Activity in EHy 926 Cultured with Lysophosphatidylcholine. Lipids 2009, 44:225–235.
13. Chen JH, Shearer GC, Chen QT, Healy CL, Beyer AJ, Nareddy VB, Gerdes AM, Harris WS, O’Connell TD, Wang DJ: Omega-3 Fatty Acids Prevent Pressure Overload-Induced Cardiac Fibrosis Through Activation of Cyclic GMP/Protein Kinase G Signaling in Cardiac Fibroblasts. Circulation 2011, 125:1484–1503.
14. Mortamais M, Artero S, Ritchie K: Cerebral white matter hyperintensities in the prediction of cognitive decline and incidental dementia. Int Rev Psychiatry 2013, 25:686–698.
15. Kandiah N, Chander R, Zhang A, Yee CC: Cerebral white matter disease is independently associated with BPSD in Alzheimer’s disease. J Neurol Sci 2014, 337:162–166.
16. Yagi S, Akaike M, Ise T, Iwasaki Y, Sata M: Renin-angiotensin-aldosterone system has a pivotal role in cognitive impairment. Hypersens Res 2013, 36:753–758.
17. Matsumoto M, Sata M, Fukuda D, Tanaka K, Soma M, Hirata Y, Nagai R: Orally administered eicosapentaenoic acid reduces and stabilizes atherosclerotic lesions in ApoE-deficient mice. Atherosclerosis 2008, 197:524–533.
18. Lin PY, Huang SY, Su KP: A meta-analytic review of polysaturated fatty acid compositions in patients with depression. Biol Psychiatry 2010, 68:140–147.
19. Freund-Levi Y, Eriksdotter-Jonhagen M, Cederholm T, Basun H, Faxen- Irving G, MIBG for the differential diagnosis of dementia – Differentiation of dementia with Lewy bodies and Alzheimer disease when the diagnoses based on clinical and neuroimaging criteria are difficult. Clin Nucl Med 2008, 33:398–401.
20. Freund-Levi Y, Eriksdotter-Jonhagen M, Cederholm T, Basun H, Faxen- Irving G, MIBG for the differential diagnosis of dementia – Differentiation of dementia with Lewy bodies and Alzheimer disease when the diagnoses based on clinical and neuroimaging criteria are difficult. Clin Nucl Med 2008, 33:398–401.
21. Moore SA: Omega-3 fatty acid preparation in patients with Alzheimer’s disease: the OmegAD study: a randomized double-blind trial. Arch Neurol 2006, 63:1402–1408.
22. Freund-Levi Y, Vedin I, Cederholm T, Basun H, Faxen Irving G, Eklotsdotter M, Hjorth S, Schultberg M, Vedsby B, Wahlund LO, Salem N Jr, Palmblad J: Transfer of omega-3 fatty acids across the blood-brain barrier after dietary supplementation with a docosahexaenoic acid-rich omega-3 fatty acid preparation in patients with Alzheimer’s disease: the OmegAD study. J Intern Med 2014, 275:428–436.
23. Moore SA: Polysaturated fatty acid synthesis and release by brain-derived cells in vitro. J Mol Neurosci 2007, 16:195–200.

Cite this article as: Yagi et al.: Serum concentration of eicosapentaenoic acid is associated with cognitive function in patients with coronary artery disease. Nutrition Journal 2014 13:112.

doi:10.1186/1475-2891-13-112